Expertise in
15
conditions

Dr. Michael J. Mccormack

Meritus Medical Center Inc
Hagerstown, MD
Expertise in
15
conditions
Specialties:Oncology
Expertise in
15
conditions
OverviewInsuranceLocationsClinical Research

Overview

Michael Mccormack is an Oncologist in Hagerstown, Maryland. Dr. Mccormack is highly rated in 15 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Virilizing Ovarian Tumor, and Ovarian Carcinosarcoma.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
Meritus Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Humana

Locations

MERITUS MEDICAL CENTER INC
11116 Medical Campus Rd, Hagerstown, MD 21742
301-790-8000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Enrollment Status: Active_not_recruiting
Publish Date: January 28, 2025
Intervention Type: Other, Drug
Study Drugs: Darolutamide, Goserelin acetate, Leuprolide acetate, Triptorelin
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Other, Drug
Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Other, Procedure
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
2016-11: Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program
2016-11: Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
View 8 Less Clinical Trials

5 Total Publications

Determinants of successful ictal SPECT injection in phase 1 epilepsy presurgical evaluation: Findings from the pediatric epilepsy research consortium surgery database project.
Determinants of successful ictal SPECT injection in phase 1 epilepsy presurgical evaluation: Findings from the pediatric epilepsy research consortium surgery database project.
Journal: Epilepsia open
Published: February 23, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Matthias Holdhoff
Oncology
Expertise in
19
conditions
Dr. Matthias Holdhoff
Oncology

Johns Hopkins University

5255 Loughboro Rd Nw, 
Washington, DC 
 (56.5 mi)
202-537-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthias Holdhoff is an Oncologist in Washington, Washington, D.c.. Dr. Holdhoff is highly rated in 19 conditions, according to our data. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

Expertise in
16
conditions
Dr. Michael A. Carducci
Oncology
Expertise in
16
conditions
Dr. Michael A. Carducci
Oncology

Johns Hopkins University

8600 Old Georgetown Rd, 
Bethesda, MD 
 (53.0 mi)
301-896-3100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Carducci is an Oncologist in Bethesda, Maryland. Dr. Carducci is highly rated in 16 conditions, according to our data. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.

Wyndham H. Wilson
Expertise in
18
conditions
Dr. Wyndham H. Wilson
Oncology
Expertise in
18
conditions
Dr. Wyndham H. Wilson
Oncology
Bethesda, MD 
 (54.3 mi)
301-435-2415
Languages Spoken:
English

Wyndham Wilson is an Oncologist in Bethesda, Maryland. Dr. Wilson is highly rated in 18 conditions, according to our data. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, and Primary Mediastinal B-Cell Lymphoma (PMBCL).

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile